After the Standing Ovation: What Changed for RAS Inhibitors in Pancreatic Cancer?

This article explores how RAS inhibition has turned from a long-standing scientific ambition into a clinical reality, specifically after ASCO 2026. We further elaborate whether this approach can move from second-line treatment to the entire pancreatic cancer treatment pathway. 

At the 2026 ASCO Annual Meeting, a standing ovation followed the presentation of RASolute 302, a phase 3 trial of the oral RAS(ON) inhibitor daraxonrasib in previously treated metastatic pancreatic adenocarcinoma. The reaction reflected more than one positive study. Just as importantly, the research question changed. The field no longer needs to ask whether RAS can be targeted in pancreatic cancer. It now needs to determine when RAS inhibition should begin, whether it should be combined with chemotherapy, and how resistance can be delayed or overcome. [1,2] 

Why the ASCO result mattered 

RASolute 302 randomized 500 patients to daraxonrasib or standard chemotherapy. Median overall survival was 13.2 months in the daraxonrasib arm versus 6.7 months in the standard of care (SOC) chemotherapy arm (Hazard ratio 0.40 [95% CI: 0.30, 0.53]; p-value <0.0001), while median progression-free survival was 7.2 months in the daraxonrasib versus 3.6 months in the SOC arm (Hazard ratio 0.49 [95% CI: 0.38, 0.64]; p-value <0.0001). These were unusually large gains in a setting where second-line options have historically provided limited benefit for metastatic pancreatic adenocarcinoma. [1,3] 

Daraxonrasib also represents a broader biological advance. Earlier RAS inhibitors generally focused on individual mutations, particularly KRAS G12C. Daraxonrasib is an oral RAS(ON) multi-selective inhibitor that suppresses oncogenic RAS signaling by targeting the active (ON) state of both mutant and wild-type (WT) variants of KRAS, NRAS, and HRAS. This wider reach is relevant because activated RAS is an oncogenic driver in over 90% of patients with pancreatic adenocarcinoma. [3,4] 

What changed after ASCO 

The most immediate change was regulatory. On August 26, 2026, the US Food and Drug Administration (FDA) approved daraxonrasib (RASONQUE, Revolution Medicines, Inc.), for adults with metastatic pancreatic adenocarcinoma who had received at least one prior systemic therapy or were not candidates for multiagent systemic therapy. The ASCO result therefore moved rapidly from a headline to a treatment option and established a new benchmark for second-line pancreatic cancer trials. [1,5] 

What comes next 

The phase 3 RASolute 303 trial is testing daraxonrasib in previously untreated metastatic disease. It compares daraxonrasib as monotherapy, or in combination with gemcitabine and nab-paclitaxel versus SOC gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic adenocarcinoma. This is relevant because most patients present with advanced, unresectable disease with only about 12% predicted to survive beyond 5 years and  <50% of patients who receive first-line therapy go on to receive second-line treatment. [6,7] The study will also show whether an oral RAS inhibitor can reduce reliance on chemotherapy or whether combination treatment provides the strongest disease control. [4,8] 

RAS inhibition is also moving into resected disease. RASolute 304 is a phase 3 trial comparing adjuvant daraxonrasib versus observation following completion of neoadjuvant and/or adjuvant chemotherapy in patients with resected pancreatic adenocarcinoma. [9,10] 

Finally, the pipeline is becoming more specialized. Zoldonrasib, an oral RAS(ON) G12D-selective covalent inhibitor, is being evaluated in phase 1/2 trials in combination regimens for patients with metastatic RAS G12D pancreatic ductal adenocarcinoma. [11] 

RAS inhibition beyond pancreatic cancer 

The significance of RAS inhibition extends well beyond pancreatic cancer. RAS proteins, particularly KRAS, are frequent oncogenic drivers in lung, colorectal and other solid tumors. The first approved KRAS inhibitors targeted the specific G12C mutation and established that direct KRAS inhibition was possible, particularly in non-small-cell lung cancer (NSCLC). However, G12C represents only one part of the RAS-mutated population, and treatment responses are often limited by adaptive pathway reactivation and acquired resistance. The field is therefore expanding toward G12D- and G12V-selective agents, broader pan-KRAS and RAS(ON) inhibitors, protein degraders and biomarker-guided combinations. Additional RAS(ON) and pan-RAS inhibitors are also under active development. Together, these agents represent a major next-generation expansion of KRAS-targeted therapy beyond single-allele inhibition.[12] 

A turning point, not an endpoint 

The standing ovation at ASCO 2026 was justified because RASolute 302 delivered phase 3 proof that pancreatic cancer’s central molecular driver can be targeted with a meaningful survival benefit. What happens next will determine the scale of that advance. If first-line and postoperative trials are positive, RAS inhibition could develop from a valuable second-line therapy into a treatment backbone across multiple stages of pancreatic cancer. If they are not, daraxonrasib will still remain an important advance, but a more limited one. 

For now, the clearest change after ASCO is that RAS has moved from an elusive research target to the organizing principle for the next generation of clinical trials. 

References 

  1. US Food and Drug Administration. FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma. FDA 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma (accessed October 13, 2026). 
  2. Osterweil N. Standing ovation at ASCO 2026 for “grand slam” pancreatic cancer data: Daraxonrasib doubles survival. Oncology News Central 2026. https://www.oncologynewscentral.com/pancreatic-cancer/standing-ovation-at-asco-2026-for-grand-slam-pancreatic-cancer-data-daraxonrasib-doubles-survival (accessed October 13, 2026). 
  3. O’Reilly EM, Wainberg ZA, Hendifar AE, et al. Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer. N Engl J Med 2026;395:325–37. https://doi.org/10.1056/NEJMoa2605555. 
  4. Seufferlein T, Hammel P, Pietrantonio F, et al. 471TiP RASolute 303: A phase III global, multicenter, open-label, randomized 3-arm study of daraxonrasib monotherapy or daraxonrasib plus gemcitabine and nab-paclitaxel versus gemcitabine and nab-paclitaxel as first-line treatment for patients with metastatic pancreatic adenocarcinoma. Ann Oncol 2026;37(Suppl 1):S171. 
  5. US Food and Drug Administration. FDA approves first-in-class targeted therapy for metastatic pancreatic cancer. FDA 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-class-targeted-therapy-metastatic-pancreatic-cancer (accessed October 13, 2026). 
  6. King G, Ittershagen S, He L, et al. Treatment patterns in US patients receiving first-line and second-line therapy for metastatic pancreatic ductal adenocarcinoma in the real world. Adv Ther 2022;39:5433–52. https://doi.org/10.1007/s12325-022-02317-9. 
  7. Halbrook CJ, Lyssiotis CA, Pasca di Magliano M, et al. Pancreatic cancer: Advances and challenges. Cell 2023;186:1729–54. https://doi.org/10.1016/j.cell.2023.02.014. 
  8. Dana-Farber Cancer Institute. RASolute 303: A phase 3 global, multicenter, open-label, randomized, 3-arm study of daraxonrasib monotherapy or daraxonrasib plus gemcitabine and nab-paclitaxel versus gemcitabine and nab-paclitaxel as first-line treatment for patients with metastatic pancreatic adenocarcinoma. n.d. https://www.dana-farber.org/clinical-trials/26-067 (accessed October 13, 2026). 
  9. Ducreux MP, Chang DK, Ikeda M, et al. 472TiP RASolute 304: A phase III multicenter, open-label, randomized study of adjuvant daraxonrasib versus observation following completion of neoadjuvant and/or adjuvant chemotherapy in patients with resected pancreatic adenocarcinoma. Ann Oncol 2026;37(Suppl 1):S172. https://doi.org/10.1016/j.annonc.2026.05.511. 
  10. Dana-Farber Cancer Institute. RASolute 304: A phase 3 multicenter, open-label, randomized, 2-arm study of adjuvant daraxonrasib versus standard-of-care observation following completion of neoadjuvant and/or adjuvant chemotherapy in patients with resected pancreatic ductal adenocarcinoma. n.d. https://www.dana-farber.org/clinical-trials/26-033 (accessed October 13, 2026). 
  11. Revolution Medicines. Revolution Medicines to present clinical data from RAS(ON) inhibitor combination trials in pancreatic cancer at ESMO Gastrointestinal Cancers Congress 2026. Revolution Medicines 2026. https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-present-clinical-data-rason-inhibitor (accessed October 13, 2026). 
  12. Kano Y. Precision targeting of KRAS-mutant cancers: Beyond G12C toward G12D and pan-RAS therapeutic strategies. Int J Mol Sci 2026;27:5796. https://doi.org/10.3390/ijms27135796.